KAIROS PHARMA LTD (KAPA)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.84+10.18%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KAPA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|---|
| Operating Expenses & Income | |||||
| R&D Expenses | 2.4 | 2.1 | 0.4 | 0.1 | — |
| Operating Income | (6.0) | (5.6) | (2.3) | (1.7) | — |
| Earnings from Continuing Operations | |||||
| Interest Expense | — | — | 0.0 | — | — |
| Other Non-Operating Income / Expenses | 0.2 | 0.1 | (0.3) | (0.1) | — |
| Net Income | |||||
| Net Income | (5.8) | (5.4) | (2.6) | (1.8) | — |
| Per Share | |||||
| Basic EPS | (0.27) | (0.30) | (0.23) | (0.17) | — |
| Diluted EPS | (0.27) | (0.30) | (0.23) | (0.17) | — |
| Basic Weighted Avg Shares | 21.4 | 18.4 | 11.4 | 10.4 | — |
| Diluted Weighted Avg Shares | 21.4 | 18.4 | 11.4 | 10.4 | — |
| Supplemental | |||||
| EBIT | (6.0) | (5.6) | (2.3) | (1.7) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.